纯度 | >95%SDS-PAGE. |
种属 | Human |
靶点 | SNRPG |
Uniprot No | P62308 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-76aa |
氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMSKAHPPELKKFMDKKLSLKLNGGRHVQGI LRGFDPFMNLVIDECVEMATSGQQNNIGMVVIRGNSIIMLEALERV |
预测分子量 | 11 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SNRPG重组蛋白的3篇参考文献示例(文献信息为示例性内容,实际引用请核实原文):
---
1. **文献名称**: *Structural insights into the role of SNRPG in spliceosome assembly*
**作者**: Lee, S. et al.
**摘要**: 本研究通过重组表达人源SNRPG蛋白,结合X射线晶体学分析其三维结构,揭示了SNRPG与U1小核核糖核蛋白(snRNP)核心组分的相互作用机制,阐明了其在剪接体早期组装中的关键作用。
2. **文献名称**: *SNRPG recombinant protein regulates alternative splicing in cancer cells*
**作者**: Zhang, Y. & Wang, H.
**摘要**: 利用重组SNRPG蛋白进行体外剪接实验,证明其通过调控特定mRNA前体的选择性剪接影响肿瘤细胞增殖,为SNRPG在癌症中的功能研究提供实验依据。
3. **文献名称**: *Functional characterization of SNRPG mutations using recombinant protein systems*
**作者**: Müller, C.W. et al.
**摘要**: 通过构建SNRPG重组蛋白突变体,结合体外剪接活性测定,揭示了SNRPG关键结构域突变导致剪接缺陷的分子机制,为遗传性剪接相关疾病的致病机理提供新见解。
---
**说明**:
- 以上文献摘要概括了SNRPG重组蛋白在结构解析、疾病机制及功能研究中的典型应用。
- 实际研究中建议通过PubMed或Web of Science检索关键词“SNRPG recombinant”或“SNRPG purification”获取具体文献。
**Background of SNRPG Recombinant Protein**
SNRPG (Small Nuclear Ribonucleoprotein Polypeptide G) is a core component of the spliceosome, a dynamic molecular machinery responsible for pre-mRNA splicing in eukaryotic cells. As part of the Sm protein family, SNRPG plays a critical role in assembling small nuclear ribonucleoproteins (snRNPs), which recognize splice sites and catalyze intron removal to generate mature mRNA. This process is essential for ensuring proper gene expression and protein diversity. Dysregulation of SNRPG has been linked to splicing errors associated with cancers, neurodegenerative disorders, and developmental defects.
Recombinant SNRPG protein is produced using genetic engineering techniques, typically by expressing the SNRPG gene in bacterial (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian or insect cells). This allows large-scale production of pure, functional protein for research and therapeutic applications. The recombinant form retains the ability to interact with other spliceosomal components, making it invaluable for studying spliceosome assembly, RNA-protein interactions, and splicing mechanisms.
In biomedical research, SNRPG recombinant protein is used to investigate its role in diseases. For example, aberrant splicing due to SNRPG dysfunction is observed in tumors, providing insights into cancer progression. It also serves as a tool for screening drugs targeting spliceosome activity. Additionally, structural studies using recombinant SNRPG help elucidate its binding motifs and conformational changes during splicing.
Overall, SNRPG recombinant protein bridges molecular biology and clinical research, offering a deeper understanding of RNA processing and its implications in health and disease.
×